Prescient Oncology Has Regained Compliance with Nasdaq’s least Bid Price Requirement

Prescient Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), concentrated on applying man-made brainpower (“AI”) to customized prescription and medication disclosure, today declared that dependent on a notice letter (the “Notice... Read more »